Identifying a New Peptide for Rheumatoid Arthritis Treatment
Author Information
Author(s): Annemieke MH Boots, Henk Hubers, Milou Kouwijzer, Leontien den Hoed-van Zandbrink, Bernice M Westrek-Esselink, Cindy van Doorn, Rachel Stenger, Ebo S Bos, Marie-jose C van Lierop, Gijs F Verheijden, Cornelis M Timmers, Catharina J van Staveren
Primary Institution: NV Organon, Research Laboratories, Oss, The Netherlands
Hypothesis
Can an altered peptide ligand based on the HC gp-39 epitope modulate T cell responses in rheumatoid arthritis?
Conclusion
The study identified a non-classical altered peptide ligand that may help in treating rheumatoid arthritis by modulating the immune response.
Supporting Evidence
- The study identified key residues in the HC gp-39 epitope that are important for T cell recognition.
- Altered peptide ligands were developed that showed potential to modulate immune responses in animal models.
- Findings suggest that the identified peptide could be beneficial for rheumatoid arthritis immunotherapy.
Takeaway
Researchers found a new peptide that might help treat rheumatoid arthritis by changing how the immune system reacts to a specific protein in the body.
Methodology
The study used T cell hybridomas from HLA-DR4 transgenic mice to identify key residues in the HC gp-39 epitope and tested modified peptides for their ability to modulate T cell responses.
Limitations
The study primarily focused on in vitro and animal models, which may not fully translate to human responses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website